Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders

Laudon, Moshe; Frydman‐Marom, Anat

doi:10.3390/ijms150915924

Cited by 116 publications

(70 citation statements)

References 173 publications

(189 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While piromelatine may positively affect both insulin resistance and lipid metabolism in rodent models of type 2 diabetes [128,162], these findings have not yet been confirmed in a controlled clinical trial. Thus, it remains to be elucidated whether melatonin or melatonin receptor agonists can be used clinically as an effective means for improving glycaemic control and normalising sleep patterns among type 2 diabetic patients, or perhaps as a preventative treatment to halt the progression of metabolic disease.…”

Section: Clinical Evidencementioning

confidence: 70%

See 1 more Smart Citation

Chronomedicine and type 2 diabetes: shining some light on melatonin

et al. 2016

View full text Add to dashboard Cite

In mammals, the circadian timing system drives rhythms of physiology and behaviour, including the daily rhythms of feeding and activity. The timing system coordinates temporal variation in the biochemical landscape with changes in nutrient intake in order to optimise energy balance and maintain metabolic homeostasis. Circadian disruption (e.g. as a result of shift work or jet lag) can disturb this continuity and increase the risk of cardiometabolic disease. Obesity and metabolic disease can also disturb the timing and amplitude of the clock in multiple organ systems, further exacerbating disease progression. As our understanding of the synergy between the timing system and metabolism has grown, an interest has emerged in the development of novel clock-targeting pharmaceuticals or nutraceuticals for the treatment of metabolic dysfunction. Recently, the pineal hormone melatonin has received some attention as a potential chronotherapeutic drug for metabolic disease. Melatonin is well known for its sleep-promoting effects and putative activity as a chronobiotic drug, stimulating coordination of biochemical oscillations through targeting the internal timing system. Melatonin affects the insulin secretory activity of the pancreatic beta cell, hepatic glucose metabolism and insulin sensitivity. Individuals with type 2 diabetes mellitus have lower night-time serum melatonin levels and increased risk of comorbid sleep disturbances compared with healthy individuals. Further, reduced melatonin levels, and mutations and/or genetic polymorphisms of the melatonin receptors are associated with an increased risk of developing type 2 diabetes. Herein we review our understanding of molecular clock control of glucose homeostasis, detail the influence of circadian disruption on glucose metabolism in critical peripheral tissues, explore the contribution of melatonin signalling to the aetiology of type 2 diabetes, and discuss the pros and cons of melatonin chronopharmacotherapy in disease management.

show abstract

Section: Clinical Evidencementioning

confidence: 70%

“…Additionally, the compound IIK7 has been developed as a melatonin receptor agonist with 90-fold higher affinity for the MT2 receptor [161]. Like IIK7, both ramelteon and tasimelteon have a greater affinity for the MT2 receptor [162].…”

Section: Clinical Evidencementioning

confidence: 99%

Chronomedicine and type 2 diabetes: shining some light on melatonin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Эффективность и пере-носимость агомелатина при лечении тяжелой депрес-сии в сравнении с плацебо была изучена в мета-ана-лизе, проведенном Koesters M. с соавт., включавшем 13 исследований. Терапия агомелатином была значимо эф-фективнее плацебо в девяти исследованиях [99% ДИ 2,29-0,73], в трех -не получено значимого превос-ходства агомелатина в сравнении с плацебо [99% ДИ 0, 48]. Однако в последних наблюдались проти-воречивые результаты, и они так и не были опублико-ваны [43].…”

Section: Antidepressants In Ischemic Heart Diseaseunclassified

“…Некоторые исследования показали положи-тельные эффекты мелатонина для лечения нарушений сна [46][47][48], но применение мелатонина ограничено его низкой биодоступностью. На сегодняшний день аго-мелатин имеют самую большую клиническую базу из всех синтетических агонистов MT1 и MT2 мелатони-новых рецепторов.…”

Section: Antidepressants In Ischemic Heart Diseaseunclassified

“…с со-авт., у пациентов с депрессией, получавших агомела-тин в дозе 25 мг/сут, полисомнография показала уве-личение продолжительности медленного сна и нор-мализацию его распределения в течение ночи после 6 нед лечения [48]. Кроме того, соматические жалобы и симптомы, связанные с нарушением сна, существенно снизились на протяжении всего исследования, что свидетельствует о благотворном влиянии агомелатина при лечении депрессии, связанной с нарушением сна.…”

Section: Antidepressants In Ischemic Heart Diseaseunclassified

See 1 more Smart Citation